Breast Cancer

Top news of the day from across the health care landscape.

Risk of developing breast cancer in women with a BRCA1 mutation may be reduced.

Women diagnosed with breast cancer who carry a BRCA mutation have up to a 50% lifetime risk of developing a second breast cancer.

Postmenopausal women with early breast cancer showed a reduction in disease recurrence after 10 years of aromatase inhibitor therapy with letrozole.

Biosimilar trastuzumab antibody (MYL-1401O) comparable in efficacy and safety to targeted cancer drug in women with HER2-positive advanced breast cancer.

Alcohol found to affect biologic mechanisms that raise the risk of cancer.

Improved cancer detection rates and a reduced recall rates can be enhanced.

Anthracycline chemotherapy for breast cancer treatment may not cause decline in cognitive function.

The PI3K/AKT pathway may provide a new therapeutic target for breast cancer combination therapy.

Treatment approach may eradicate triple-negative breast cancer.

Cancer diagnosis may potentially cause a decrease in physical function and mental health.

Cisplatin kills both rapidly dividing cells and non-dividing cells in the inner ear, which can lead to hearing loss.

Epigenetic changes can leave cancer stem cells vulnerable to a combination of 5-azacytidine and butyrate.

Targaprimir-96 causes programmed cell death in breast cancer animal models.

Top news of the day from across the health care landscape.

Blocking estrogen production by using an aromatase inhibitor stopped seizures in animal models.

Patients taking mitoxantrone for multiple sclerosis found to have higher rates of breast and colorectal cancers and leukemia.

Patients administered mitoxantrone for multiple sclerosis carry higher rates of breast and colorectal cancers and leukemia.

The small molecule drug, SI-2, found to improve cancer treatment in mouse models.

Women with proliferating cells within mammary epithelium cells significantly more likely to develop breast cancer.

Infertility and breast density may impact the risk of cancer.

Infertility and breast density may impact the risk of cancer.

JAK2 could potentially cause treatment resistance in TNBC.

JAK2 could potentially cause treatment resistance in TNBC.

Treatment costs climb with advanced-stage breast cancer compared with earlier stages.